Details for New Drug Application (NDA): 213978
✉ Email this page to a colleague
The generic ingredient in TYRVAYA is varenicline tartrate. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
Summary for 213978
| Tradename: | TYRVAYA |
| Applicant: | Oyster Point Pharma |
| Ingredient: | varenicline tartrate |
| Patents: | 10 |
Pharmacology for NDA: 213978
| Mechanism of Action | Cholinergic Agonists Partial Cholinergic Nicotinic Agonists |
Medical Subject Heading (MeSH) Categories for 213978
Suppliers and Packaging for NDA: 213978
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Oyster Point Pharma, Inc. | 73521-030 | 73521-030-02 | 2 BOTTLE, PUMP in 1 CARTON (73521-030-02) / 4.2 mL in 1 BOTTLE, PUMP |
| TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978 | NDA | Oyster Point Pharma, Inc. | 73521-030 | 73521-030-90 | 1 BOTTLE, PUMP in 1 CARTON (73521-030-90) / 4.2 mL in 1 BOTTLE, PUMP |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;NASAL | Strength | EQ 0.03MG BASE/SPRAY | ||||
| Approval Date: | Oct 15, 2021 | TE: | RLD: | Yes | |||||
| Patent: | 10,456,396 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
| Patent: | 11,224,598 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
| Patent: | 11,903,941 | Patent Expiration: | Oct 19, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) | ||||||||
Complete Access Available with Subscription
